<DOC>
	<DOCNO>NCT02521610</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , ascending-dose , parallel-group study evaluate pharmacodynamic effect , pharmacokinetics , safety , tolerability one week RG7625 dose healthy male female volunteer . Each participant receive single dose RG7625 placebo follow one week dose treatment . Each participant also receive intradermal administration 4 recall antigen Screening Day 7 treatment ass study drug effect delayed-type hypersensitivity ( DTH ) .</brief_summary>
	<brief_title>A Multiple Ascending-Dose Study RG7625 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy adult male females 18 60 year age , inclusive Body mass index 18.0 30.0 kilogram per metersquared ( kg/m^2 ) , inclusive Any clinically relevant abnormality , concomitant disease ongoing medical condition , abnormal laboratory test result , history clinically significant disorder Any major illness within one month precede Screening visit , febrile illness within two week precede Screening visit Any significant allergic reaction drug Immunocompromised reduce immune function and/or immunization within 30 day first study drug administration plan vaccination study Women pregnant lactate childbearing potential Clinically significant abnormal electrocardiogram ( ECG ) risk factor QT prolongation Use prescribe overthecounter medication Inability unwillingness comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>